Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juliano Timm

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|September 2, 2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant TuberculosisFrancesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, et al.
The Journal of Antimicrobial Chemotherapy|March 9, 2022
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanidAnna Bateson, Julio Ortiz Canseco, Timothy D McHugh, et al.
The Lancet. Infectious Diseases|May 20, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMuge Cevik, Lindsay C Thompson, Caryn Upton, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|September 2, 2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant TuberculosisFrancesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, et al.
The Journal of Antimicrobial Chemotherapy|March 9, 2022
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanidAnna Bateson, Julio Ortiz Canseco, Timothy D McHugh, et al.
The Lancet. Infectious Diseases|May 20, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMuge Cevik, Lindsay C Thompson, Caryn Upton, et al.
Pageof 2